MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70241

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome.

Sauer Mathias, Gomes Bárbara Fernandes, Shahrouki Parasto, Lantero-Rodriguez Juan, Montoliu-Gaya Laia, Camporesi Elena, Belbin Olivia, Alcolea Daniel, Kumar Ashish, Sharma Mitu, Singh Sangeeta, Brinkmalm Gunnar, Gobom Johan, Carmona-Iragui María, Schöll Michael, Janelidze Shorena, Deep Gagan, Blennow Kaj, Zetterberg Henrik, Brinkmalm Ann, Lleó Alberto, Fortea Juan, Hansson Oskar, Ashton Nicholas J, Nilsson Johanna

СтатьяВалидационное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Synaptic dysfunction and loss are pathological hallmarks of neurodegenerative diseases. Neuronal pentraxin 2 (NPTX2), a presynaptic protein involved in synaptic plasticity, has been linked to cognitive decline in Alzheimer's disease (AD) and other neurodegenerative disorders.

METHODS

We developed and validated a novel single molecule array (Simoa) for NPTX2 in cerebrospinal fluid, which was evaluated in two independent cohorts.

RESULTS

CSF NPTX2 concentration was lower (fold change [FC] 0.82, p < 0.01) in AD patients and Down syndrome individuals (FC 0.56, p < 0.001), compared with cognitively unimpaired patients (CU). It was also associated with Mini-Mental State Examination (MMSE) score (β = 2.51, p < 0.001), tau-PET (β = -0.21, p < 0.01), and cortical thickness (β = 0.08, p < 0.001).

DISCUSSION: We describe the first assay for NPTX2 on the Simoa platform, where we continue to highlight the valuable addition of NPTX2 to routine diagnostics of suspected cognitive impairment in patients as it associates better with cognition than other, more established AD biomarkers.

HIGHLIGHTS: Novel method validated for measuring CSF NPTX2 on semi-automated Simoa platform. Method validated for use in CSF, where it shows a significant decrease in both AD and DS patients. Associated with cognition, neurofibrillary tangles, and cortical thickness in AD patients. Associations with cognition are shown to be stronger than those of pTau and NFL.

Для цитирования: Sauer Mathias, Gomes Bárbara Fernandes, Shahrouki Parasto, Lantero-Rodriguez Juan, Montoliu-Gaya Laia, Camporesi Elena, Belbin Olivia, Alcolea Daniel, Kumar Ashish, Sharma Mitu, Singh Sangeeta, Brinkmalm Gunnar, Gobom Johan, Carmona-Iragui María, Schöll Michael, Janelidze Shorena, Deep Gagan, Blennow Kaj, Zetterberg Henrik, Brinkmalm Ann, Lleó Alberto, Fortea Juan, Hansson Oskar, Ashton Nicholas J, Nilsson Johanna. Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70241.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.